Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

As massive capital flows into the life science sector, two distinct, and potentially opposing, strategic directions have emerged. While NVIDIA (NASDAQ:NVDA) is expanding its healthcare presence ...

Pfizer Inc. (PFE) released mid-stage clinical trial data for its high-profile obesity drug candidate PF-3944 on Tuesday, sending its shares down more than 3%. The data presented a classic ...

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

By Christy Santhosh Jan 29 (Reuters) - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up ...

Both companies may succeed in this industry.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Drugmaker Eli Lilly and Co. says it'll build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands ...

Eli Lilly is expanding its footprint in eastern Pennsylvania with a new manufacturing site outside of Philadelphia. The global pharmaceutical company revealed plans today to build a $3.5 billion drug ...

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Real estate investor Matt Theriault asks whether lower mortgage rates will return to the housing market soon. Opinion: Trump isn’t ‘screwing around’ with our elections — it’s dangerous to suggest he ...

As Canada prepares for generic weight-loss drugs, the benefits for metabolic diseases come with weightier expectations that we should all be skinny ...